Business Wire

Skechers Responds to Kizik’s Patent Lawsuit

Share

Skechers USA, Inc. (“Skechers”), the Comfort Technology Company and leader in hands-free footwear technology, announced today that it will vigorously defend the patent suit filed in Texas federal court against Skechers by Kizik Design, LLC (“Kizik”) alleging,in essence, that the entire line of Skechers Hands Free Slip-ins® (“Slip-ins”) infringe Kizik’s patents. The Company believes that Kizik’s allegations are baseless.

As owners of a vast portfolio of intellectual property, Skechers respects the rights of others. Kizik’s complaint is based on the assertion that Kizik created the hands-free footwear category and is the only company that can legally use that century-old idea. Contrary to Kizik’s false assertion that Skechers patents have been rejected, Skechers has developed its own unique Slip-ins technology and has obtained more than 140 utility and design patents worldwide, including in the United States, and has vigilantly enforced its patent rights, resulting in numerous judgements, injunctions and settlements around the world.

Michael Greenberg, President of Skechers, stated, “The timing of this lawsuit is curious, coming on the heels of Skechers announcing a $9.42 billion merger with 3G Capital. Kizik asserts that, ‘at the heart of Skechers’ hands-free shoes’ are Kizik’s patented technologies, yet Skechers has been advertising and selling its Slip-ins since December 2021 without so much as a letter from Kizik. Then, after the merger is announced, Kizik hires a law firm also used by Nike and attacks our whole Slip-ins product line. We believe that, after all these years of silence, the true motivation for this lawsuit might be found right on the face of Kizik’s complaint, where they state that they are looking for a share of the $9.42 billion being paid for Skechers, money Kizik did not earn and does not deserve.”

Mr. Greenberg continued: “Hands-free footwear has been around for at least a century. It was not created in the 21st Century in Utah. We have become the market leader in the hands-free footwear space by innovating – not imitating – this idea into a true hands-free fit with our own technology. Skechers invests tremendous resources into research and development to introduce its own fresh, unique and exciting footwear to customers year in and year out and will continue to do so, undeterred by transparent litigation efforts to thwart competition. We will aggressively challenge both the validity of the patents and the infringement claims.”

About SKECHERS U.S.A., Inc.

Skechers (NYSE:SKX), The Comfort Technology Company® based in Southern California, designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company’s collections are available in 180 countries and territories through department and specialty stores, and direct to consumers through skechers.com and more than 5,300 Skechers retail stores. A Fortune 500® company, Skechers manages its international business through a network of wholly-owned subsidiaries, joint venture partners, and distributors. For more information, please visit about.skechers.com and follow us on FacebookInstagram and TikTok.

This announcement contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include, without limitation, Skechers’ future domestic and international growth, financial results and operations including expected net sales and earnings, its development of new products, future demand for its products, its planned domestic and international expansion, opening of new stores and additional expenditures, and advertising and marketing initiatives. Forward-looking statements can be identified by the use of forward-looking language such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “plan,” “project,” “will,” “could,” “may,” “might,” or any variations of such words with similar meanings. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements. Factors that might cause or contribute to such differences include the disruption of business and operations due to the COVID-19 pandemic; delays or disruptions in our supply chain; international economic, political and market conditions including the effects of inflation, tariffs and foreign currency exchange rate fluctuations around the world, the challenging consumer retail markets in the United States, and the impact of wars, acts of war and other conflicts around the world; sustaining, managing and forecasting costs and proper inventory levels; losing any significant customers; decreased demand by industry retailers and cancellation of order commitments due to the lack of popularity of particular designs and/or categories of products; maintaining brand image and intense competition among sellers of footwear for consumers, especially in the highly competitive performance footwear market; anticipating, identifying, interpreting or forecasting changes in fashion trends, consumer demand for the products and the various market factors described above; sales levels during the spring, back-to-school and holiday selling seasons; and other factors referenced or incorporated by reference in Skechers’ annual report on Form 10-K for the year ended December 31, 2024 and its quarterly reports on Form 10-Q in 2025. Taking these and other risk factors associated with the COVID-19 pandemic into consideration, the dynamic nature of these circumstances means that what is stated in this press release could change at any time, and as a result, actual results could differ materially from those contemplated by such forward-looking statements. The risks included here are not exhaustive. Skechers operates in a very competitive and rapidly changing environment. New risks emerge from time to time and we cannot predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on forward-looking statements as a prediction of actual results. Moreover, reported results should not be considered an indication of future performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250728674864/en/

Contacts

Media Contact:
Jennifer Clay
SKECHERS U.S.A., Inc.
jennc@skechers.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Announces Seamless Azure DevOps Integration for Effortless Test Management29.7.2025 18:30:00 EEST | Press release

LambdaTest, a GenAI-powered quality engineering platform, is excited to announce the launch of its Azure DevOps App, designed to streamline test management within the Azure DevOps environment. The LambdaTest Azure DevOps App integrates directly with Azure DevOps through the Azure DevOps Marketplace, providing users with a powerful tool to manage and track their executions. They can also link test cases, track executions of those test cases, and create new test cases with AI or manually in a seamless manner, boosting workflow efficiency and fostering better collaboration across development teams. The LambdaTest AI Test Manager, which is available through the Azure DevOps Marketplace, enhances the Azure DevOps interface by bringing test management functionalities right where teams are already working. This direct integration allows developers and testers to efficiently handle test cases, whether creating, linking, or tracking them, without switching between different tools or environment

Rigaku Launches XTRAIA XD-3300 Mass Production for Semiconductor Market29.7.2025 17:00:00 EEST | Press release

Rigaku Corporation, a global solution partner in X-ray metrology systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), has launched full-fledged commercial production of XTRAIA XD-3300, a high-resolution microspot X-ray diffraction system This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250729915168/en/ XTRAIA XD-3300 Against a background of demand for generative AI and data centers, scaling and 3D realization of semiconductors are advancing at unprecedented speed. Needs are growing for next-generation memory such as high-bandwidth memory (HBM) and 3D DRAM as well as 2 nm and subsequent generations of logic semiconductor. To secure high performance in these devices, chipmakers are increasingly adopting superlattices (nanoscale integrated structures) using Si/SiGe (silicon/silicon-germanium) processes. To control these advanced internal structures ap

AQNEURSA ® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C29.7.2025 16:27:00 EEST | Press release

IntraBio Inc., a biopharmaceutical company focused on developing therapies for rare neurological diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of AQNEURSA® (levacetylleucine) for the treatment of Niemann-Pick disease type C (NPC). "This positive CHMP opinion represents another important milestone in expanding access to AQNEURSA to the global NPC community," said Dr. Marc Patterson, Chief Medical Officer of IntraBio. "The recommendation reflects the strength of our clinical data and the potential for AQNEURSA to be a foundational therapy for NPC, delivering meaningful benefits for patients. We are proud to work alongside the NPC community to bring this long-awaited treatment option to even more families.” NPC is a rare, inherited lysosomal disorder characterized by progressive neurological deterioration, leading to loss of motor function, difficulties with spe

NetJets Empowers Pilots With Cutting-Edge Safety Analytics From FlightPulse ®29.7.2025 16:05:00 EEST | Press release

Recognized worldwide for its safety-first focus, NetJets, the global private aviation leader, today announced the adoption of FlightPulse® from GE Aerospace across its operations in the United States and Europe, providing pilots with data to increase safety and efficiency from takeoff to landing. FlightPulse® will equip NetJets’ more than 4,400 pilots globally with secure, consolidated flight data to drive informed decisions on risk management, aircraft functionality and fuel, and their own performance, fostering continuous self-improvement. NetJets is the first private jet operator of its kind to embrace the technology, which it plans to begin deploying by the end of the year. “In the world of aviation, safety is paramount and will always be NetJets’ first and highest priority, integral to every decision we make,” said Adam Johnson, NetJets Chairman and CEO. “As the industry leader, it is our responsibility to elevate our safety programs by utilizing cutting-edge tools like FlightPuls

New Torq AMP Alliance Program Debuts with Armis As a Launch Partner to Accelerate Autonomous SecOps29.7.2025 16:00:00 EEST | Press release

Armis, the cyber exposure management & security company, today announced it has been selected as a launch partner for the Torq AMP alliance program, designed to drive agentic AI innovation. Armis was chosen due to its leading Cyber Exposure Management Platform, Armis CentrixTM, that seamlessly integrates with Torq’s SecOps platform to empower customers and their SOC/Incident Response teams. “As the leader in Cyber Exposure Management, Armis is redefining how organizations understand, prioritize, and reduce risk across their entire attack surface,” said Nadir Izrael, CTO and Co-Founder of Armis. “Our AI-driven platform provides unmatched visibility and contextual intelligence across IT, OT, IoT, medical, and cloud assets—empowering security teams to act decisively. That’s why we’re excited to join Torq’s AMP Alliance. The combination of Armis Centrix™ and Torq’s agentic AI delivers a new level of SecOps automation, where detection, enrichment, and response happen in real time, with prec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye